Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: A three-dimensional (3-D), polyacrylamide gel-based DNA microarray method

Technology in Cancer Research and Treatment

Volumn 12, Issue 5, 2013, Pages 473-482

  Cheng, Hongyan ^a   Qin, Qin ^b   Sun, Xinchen ^b   Li, Fan ^a   Sun, Ning ^a   Cheng, Lu ^a   Lu, Zuhong ^a   Chen, Baoan ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Non small cell lung cancer; Single nucleotide polymorphism (SNP); Survival; XPA; XPD

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; POLYACRYLAMIDE GEL; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA; ERCC2 PROTEIN, HUMAN; TAXOID; VINBLASTINE; XPA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TAXOIDS; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84884132007     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.7785/tcrt.2012.500337     Document Type: Article

References (61)

1. Yang, L., Parkin, D. M., Li, L. D., Chen, Y. D., Bray, F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 90, 2157-2166 (2004). DOI: 10.1038/ sj.bjc.6601813
2. Cheng, H., Sun, N., Sun, X., Chen, B., Li, F., Feng, J., Cheng, L., Cao, Y. Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochim Biophys Sin (Shanghai) 42, 311-317 (2010). DOI: 10.1093/abbs/gmq023
3. Guilbert, J. J. The world health report 2002-reducing risks, promoting healthy life. Educ Health (Abingdon) 16, 230 (2003). DOI: 10.1080/1357628031000116808
4. Spiro, S. G., Silvestri, G. A. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 11, 287-291 (2005).
5. Hoffman, P. C., Mauer, A. M., Vokes, E. E. Lung cancer. Lancet 355, 479-485 (2000). DOI: 10.1016/S0140-6736(00)82038-3
6. Bunn, P. A., Jr, Kelly, K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4, 1087-1100 (1998).
7. Rabik, C. A., Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33, 9-23 (2007). DOI: 10.1016/j.ctrv.2006.09.006
8. Viktorsson, K., De Petris L., Lewensohn, R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331, 868-880 (2005). DOI: 10.1016/j.bbrc.2005.03.192
9. Bernig, T., Chanock, S. J. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6, 319-331 (2006). DOI: 10.1586/14737159.6.3.319
10. Volker, M., Mone, M. J., Karmakar, P., van, H. A., Schul, W., Vermeulen, W., Hoeijmakers, J. H., van, D. R., van, Z. A. A., Mullenders, L. H. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8, 213-224 (2001). DOI: 10.1016/ S1097-2765(01)00281-7
11. Chen, X., Sun, H., Ren, S., Kim, C. V., Zhang, L., Zhou, S., Zhang, J., Zhou, C. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14, 207-213 (2012). DOI: 10.1007/s12094-012-0785-3
12. Zhu, X. L., Sun, X. C., Chen, B. A., Sun, N., Cheng, H. Y., Li, F., Zhang, H. M., Feng, J. F., Qin, S. K., Cheng, L., Lu, Z. H. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small cell lung cancer. Chin Med J 123, 3427-3432 (2010). DOI: 10.3760/cma.j.i ssn.0366-6999.2010.23.010
13. Liu, L., Yuan, P., Wu, C., Zhang, X., Wang, F., Guo, H., Zhong, R., Xu, Y., Wu, J., Yu, D., Wu, T., Zhang, X., Nie, S., Miao, X., Lin, D. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73, 110-115 (2011). DOI: 10.1016/j.lungcan.2010.11.004
14. Zhou, C., Ren, S., Zhou, S., Zhang, L., Su, C., Zhang, Z., Deng, Q., Zhang, J. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40, 954-960 (2010). DOI: 10.1093/jjco/hyq071
15. Kalikaki, A., Kanaki, M., Vassalou, H., Souglakos, J., Voutsina, A., Georgoulias, V., Mavroudis, D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small cell lung cancer. Clin Lung Cancer 10, 118-123 (2009). DOI: 10.3816/ CLC.2009.n.015
16. Wu, W., Li, H., Wang, H., Zhao, X., Gao, Z., Qiao, R., Zhang, W., Qian, J., Wang, J., Chen, H., Wei, Q., Han, B., Lu, D. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS One 7, e33200 (2012). DOI: 10.1371/journal.pone.0033200
17. Yao, C. Y., Huang, X. E., Li, C., Shen, H. B., Shi, M. Q., Feng, J. F., Pan, L. X., Tang, J. H. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non-small cell lung cancers. Asian Pac J Cancer Prev 10, 859-864 (2009).
18. Giachino, D. F., Ghio, P., Regazzoni, S., Mandrile, G., Novello, S., Selvaggi, G., Gregori, D., DeMarchi, M., Scagliotti, G. V. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399G in single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13, 2876-2881 (2007). DOI: 10.1158/1078-0432.CCR-06-2543
19. Kalikaki, A., Kanaki, M., Vassalou, H., Souglakos, J., Voutsina, A., Georgoulias, V., Mavroudis, D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small cell lung cancer. Clin Lung Cancer 10, 118-123 (2009). DOI: 10.3816/ CLC.2009.n.015
20. Li, F., Sun, X., Sun, N., Qin, S., Cheng, H., Feng, J., Chen, B., Cheng, L., Lu, Z., Ji, J., Zhou, Y. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 33, 489-494 (2010). DOI: 10.1097/COC.0b013e3181b9cedc
21. Feng, J., Sun, X., Sun, N., Qin, S., Li, F., Cheng, H., Chen, B., Cao, Y., Ma, J., Cheng, L., Lu, Z., Ji, J., Zhou, Y. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 41, 429-435 (2009). DOI: 10.1093/abbs/ gmp027
22. Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981). DOI: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
23. Xiao, P. F., Cheng, L., Wan, Y., Sun, B. L., Chen, Z. Z., Zhang, S. Y., Zhang, C. Z., Zhou, G. H., Lu, Z. H. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 27, 3904-3915 (2006). DOI: 10.1002/elps.200500918
24. Wu, X., Zhao, H., Wei, Q., Amos, C. I., Zhang, K., Guo, Z., Qiao, Y., Hong, W. K., Spitz, M. R. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 24, 505-509 (2003). DOI: 10.1093/carcin/24.3.505
25. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346, 92-98 (2002). DOI: 10.1056/NEJMoa011954
26. Kelly, K., Crowley, J., Bunn, P. A. Jr., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., Israel, V. K., Livingston, R. B., Gandara, D. R. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial. J Clin Oncol 19, 3210-3218 (2001).
27. Yamamoto, K., Yamamoto, M., Hanada, K., Nogi, Y., Matsuyama, T., Muramatsu, M. Multiple protein-protein interactions by RNA polymerase I-associated factor PAF49 and role of PAF49 in rRNA transcription. Mol Cell Biol 24, 6338-6349 (2004). DOI: 10.1128/ MCB.24.14.6338-6349.2004
28. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., Poirier, M. C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 84, 5024-5028 (1987).
29. van de Vaart, P. J., Belderbos, J., de Jong, D., Sneeuw, K. C., Majoor, D., Bartelink, H., Begg, A. C. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89, 160-166 (2000). DOI: 10.1002/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO; 2-J
30. Bosken, C. H., Wei, Q., Amos, C. I., Spitz, M. R. An analysis of DNA repair as a determinant of survival in patients with non-small cell lung cancer. J Natl Cancer Inst 94, 1091-1099 (2002). DOI: 10.1093/jnci/94.14.1091
31. Reed, E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24, 331-344 (1998). DOI: 10.1016/S0305-7372(98)90056-1
32. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K., Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73, 39-85 (2004). DOI: 10.1146/ annurev.biochem.73.011303.073723
33. Guillem, V., Tormo, M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 49, 204-217 (2008). DOI: 10.1080/10428190701769657
34. Gao, R., Price, D. K., Sissung, T., Reed, E., Figg, W. D. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 7, 1246-1250 (2008). DOI: 10.1158/1535-7163.MCT-07-2206
35. Sun, N., Sun, X., Chen, B., Cheng, H., Feng, J., Cheng, L., Lu, Z. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65, 437-446 (2010). DOI: 10.1007/s00280-009-1046-1
36. Wu, X., Fan, W., Xu, S., Zhou, Y. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 9, 5874-5879 (2003).
37. Liu, J., Zhang, Z., Cao, X. L., Lei, D. P., Wang, Z. Q., Jin, T., Pan, X. L. XPA A23G polymorphism and susceptibility to cancer: a meta-analysis. Mol Biol Rep 39, 6791-6799 (2012). DOI: 10.1007/ s11033-012-1504-4
38. Peters, G. J., Bergman, A. M., Ruiz van H. V. W., Veerman, G., Kuiper, C. M., Braakhuis, B. J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22, 72-79 (1995).
39. Bergman, A. M., Ruiz van H. V. W., Veerman, G., Kuiper, C. M., Peters, G. J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2, 521-530 (1996).
40. Lunn, R. M., Helzlsouer, K. J., Parshad, R., Umbach, D. M., Harris, E. L., Sanford, K. K., Bell, D. A. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21, 551-555 (2000). DOI: 10.1093/carcin/21.4.551
41. Spitz, M. R., Wu, X., Wang, Y., Wang, L. E., Shete, S., Amos, C. I., Guo, Z., Lei, L., Mohrenweiser, H., Wei, Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61, 1354-1357 (2001).
42. Park, D. J., Stoehlmacher, J., Zhang, W., Tsao-Wei, D. D., Groshen, S., Lenz, H. J. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61, 8654-8658 (2001).
43. Stoehlmacher, J., Park, D. J., Zhang, W., Yang, D., Groshen, S., Zahedy, S., Lenz, H. J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91, 344-354 (2004). DOI: 10.1038/sj.bjc.6601975
44. Allan, J. M., Smith, A. G., Wheatley, K., Hills, R. K., Travis, L. B., Hill, D. A., Swirsky, D. M., Morgan, G. J., Wild, C. P. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104, 3872-3877 (2004). DOI: 10.1182/blood-2004-06-2161
45. Chew, H. K., Doroshow, J. H., Frankel, P., Margolin, K. A., Somlo, G., Lenz, H. J., Gordon, M., Zhang, W., Yang, D., Russell, C., et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27, 2163-2169 (2009). DOI: 10.1200/JCO.2008.17.4839
46. Stohlmacher, J. Pharmacogenetics in gastrointestinal tumors. Onkologie 28, 435-440 (2005). DOI: 10.1159/000086499
47. Kweekel, D. M., Gelderblom, H., Guchelaar, H. J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31, 90-105 (2005). DOI: 10.1016/j.ctrv.2004.12.006
48. Robert, J., Morvan, V. L., Smith, D., Pourquier, P., Bonnet, J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54, 171-196 (2005). DOI: 10.1016/j. critrevonc.2005.01.005
49. Zienolddiny, S., Campa, D., Lind, H., Ryberg, D., Skaug, V., Stangeland, L., Phillips, D. H., Canzian, F., Haugen, A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27, 560-567 (2006). DOI: 10.1093/carcin/bgi232
50. Yin, Z., Su, M., Li, X., Li, M., Ma, R., He, Q., Zhou, B. ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. J Exp Clin Cancer Res 28, 153 (2009). DOI: 10.1186/1756-9966-28-153
51. Yin, J., Vogel, U., Ma, Y., Qi, R., Sun, Z., Wang, H. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population. Cancer Genet Cytogenet 175, 47-51 (2007). DOI: 10.1016/j. cancergencyto.2007.01.010
52. Feng, Z., Ni, Y., Dong, W., Shen, H., Du J. (2012). Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis. Mol Biol Rep 39, 57-69. DOI: 10.1007/s11033-011-0710-9
53. Ludovini, V., Floriani, I., Pistola, L., Minotti, V., Meacci, M., Chiari, R., Garavaglia, D., Tofanetti, F. R., Flacco, A., Siggillino, A., Baldelli, E., Tonato, M., Crino, L. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 6, 2018-2026 (2011). DOI: 10.1097/JTO.0b013e3182307e1f
54. Ryu, J. S., Hong, Y. C., Han, H. S., Lee, J. E., Kim, S., Park, Y. M., Kim, Y. C., Hwang, T. S. Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44, 311-316 (2004). DOI: 10.1016/j.lungcan.2003.11.019
55. Giovannetti, E., Pacetti, P., Reni, M., Leon, L. G., Mambrini, A., Vasile, E., Ghidini, M., Funel, N., Lucchesi, M., Cereda, S., et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 12, 1641-1652 (2011). DOI: 10.2217/pgs.11.109
56. Li, Y., Huang, X. E., Jin, G. F., Shen, H. B., Xu, L. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev 12, 739-742 (2011).
57. Shi, M. M. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 47, 164-172 (2001).
58. Xiao, P. F., Cheng, L., Wan, Y., Sun, B. L., Chen, Z. Z., Zhang, S. Y., Zhang, C. Z., Zhou, G. H., Lu, Z. H. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 27, 3904-3915(2006). DOI: 10.1002/elps.200500918.
59. Wang, Y., Zhang, D., Zheng, W., Luo, J., Bai, Y., Lu, Z. Multiple gene methylation of non small cell lung cancers evaluated with 3-dimensional microarray. Cancer 112, 1325-1336 (2008). DOI: 10.1002/cncr.23312
60. Wan, Y., Wang, Y., Luo, J., Lu, Z. Bisulfite modification of immobilized DNAs for methylation detection. Biosens Bioelectron 22, 2415-2421 (2007). DOI: 10.1016/j.bios.2006.08.033
61. Xiao, P., Huang, H., Zhou, G., Lu, Z. Gel immobilization of acrylamide-modified single-stranded DNA template for pyrosequencing. Electrophoresis 28, 1903-1912 (2007). DOI: 10.1002/ elps.200600794.